Sandborn William J.'s Form 4 filing
Ventyx Biosciences, Inc. (VTYX) · filed Jun 27, 2023
- Accession no.
- 0001209191-23-039960
- Filed
- Jun 27, 2023, 6:01 PM ET
- Trade date
- Jun 23, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $352.8K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sandborn William J.CIK 0001923805 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 23, 2023 | Common Stock | MOption exerciseAcquired | +10,790 | $0.20 | +$2,158 | 59,179 | Direct | |
| Jun 23, 2023 | Common Stock | SSaleDisposed | −2,115 | $32.10F2 | −$67,891.92 | 57,064 | Direct | |
| Jun 23, 2023 | Common Stock | SSaleDisposed | −8,675 | $32.85F3 | −$284,952.06 | 48,389 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 23, 2023 | Common Stock | MOption exerciseDisposed | −10,790 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average share price of an aggregate total of 2,115 shares sold in the price range of $31.51 to $32.4136. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
Represents the weighted average share price of an aggregate total of 8,675 shares sold in the price range of $32.5854 to $33.5094. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
Remarks
President and Chief Medical Officer